Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials
Journal of Acquired Immune Deficiency Syndromes, Volume 60, No. 1, Year 2012